NIKKEI 225
29,685.37+2.00(+0.01%)HANG SENG
29,106.15+136.44(+0.47%)CRUDE OIL
63.36+0.23(+0.36%)
Vifor Pharma AG (0RPD.L)
| Previous close | 137.15 |
| Open | 137.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 135.20 - 137.40 |
| 52-week range | 135.20 - 137.40 |
| Volume | 3,293 |
| Avg. volume | N/A |
| Market cap | 8.777B |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | 24.52 |
| EPS (TTM) | 5.53 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vifor Pharma and Cara Therapeutics announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus
Regulatory News: Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients.
- Business Wire
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
- Business Wire
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc. today announced topline data from the ACCOLADE clinical study, the largest, randomized, blinded, placebo-controlled phase-II trial in the ultra-rare kidney disease C3 glomerulopathy (C3G) to date, which evaluated avacopan for the treatment of that disorder. Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor.
